Cure TV

Being diagnosed with a rare cancer like GIST can be overwhelming, highlighting the need for support networks, says Dr. Rosario Ligresti.

Dr. Prithviraj Bose discusses how patients with myelofibrosis can better understand their options and access the most up-to-date advancements in care.

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Dr. Rosario Ligresti explained that while many GISTs are found incidentally, larger tumors may cause anemia, bleeding or swallowing issues.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.

CURE spoke with the patient advocate and author of “Between Two Kingdoms” and “The Book of Alchemy.”

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.

Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer.

Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.

How can colonoscopy detect colorectal cancer early and prevent it by removing polyps, compared with other noninvasive screening methods?

CURE spoke with the author of “Between Two Kingdoms” and “The Book of Alchemy” about the latest chapter in her cancer journey.

Advances in leukemia treatment now include targeted drugs, lighter chemotherapy and combination regimens that improve tolerance and reduce resistance.

Patients can best advocate for themselves by asking questions and remembering they have the right to be active participants in their care.

Dr. Paul Gellhaus says PSA testing and modern biopsy methods ease fears and reassure patients, making early prostate cancer detection safe and valuable.

Elahere, validated in a phase 3 trial, is FDA-approved and offers the first major advancement for platinum-resistant ovarian cancer in decades.

In an interview, Dr. David A. Taub highlighted Prostate Cancer Awareness Month by outlining current treatment options for patients with prostate cancer.

CURE sat down with Dr. Tanja A. Gruber of Stanford Medicine Children’s Health to discuss clinical trials in infant leukemia.

Stage 1 melanoma is treatable with surgery, and when combined with early detection, proper care and regular follow-ups, it offers a favorable outlook.

Patients with breast cancer receiving antibody-drug conjugates after chemo can generally expect milder side effects compared with their previous treatment.

Genetic testing before chemotherapy may help improve safety and guide treatment for patients with gastrointestinal cancers.

For many women facing cancer, having a female oncologist can bring an added sense of support and understanding, according to Dr. Tran Ho.